Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients
Sponsor: National Taiwan University Hospital
Summary
This study is a prospective, randomized, controlled clinical trial comparing the efficacy of a 24-month cyclic therapy regimen (6 months of Romosozumab followed by 6 months of Denosumab, repeated for two years) versus a traditional sequential treatment regimen (12 months of Romosozumab followed by 12 months of Denosumab). The goal is to determine which approach yields better therapeutic outcomes and to optimize drug strategies for osteoporosis patients.
Official title: Effects of Cycle Therapy With Romosozumab and Denosumab 2 Years vs 1 Year Romosozumab Followed by 1 Year Denosumab in Postmenopausal Osteoporosis Patients-A Randomized Control Trial
Key Details
Gender
FEMALE
Age Range
50 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2025-04-08
Completion Date
2029-12-31
Last Updated
2025-12-19
Healthy Volunteers
No
Conditions
Interventions
Romosozumab followed by Denosumab
Romosozumab 210mg/month for 12 months, then Denosumab 60mg/6months for 12 months
Romosozumab and Denosumab Cycle Therapy
Romosozumab 210mg/month for 6 months then followed by Denosumab 60mg/6months once, and then repeat one more time after 6 months
Locations (1)
National Taiwan University Hospital
Taipei, Taiwan